Merck to Acquire Verona Pharma, Launching First-In-Class COPD Treatment Ohtuvayre®
Originally Published 6 months ago — by Merck.com
Merck is acquiring Verona Pharma for approximately $10 billion to expand its portfolio with Ohtuvayre, a first-in-class COPD treatment approved by the FDA, aiming to enhance growth and innovation in respiratory therapies.